Olfr829 is a member of the olfactory receptor family, which are G-protein coupled receptors (GPCRs) primarily involved in the detection of odorants. These receptors are characterized by their ability to bind specific ligands and initiate a cascade of intracellular events leading to the perception of smell. The exact physiological roles and signaling pathways of many individual olfactory receptors, including Olfr829, remain to be fully elucidated. This gap in knowledge presents challenges in identifying direct inhibitors or modulators of Olfr829. The inhibition or modulation of Olfr829, as with other olfactory receptors, can be conceptualized through the understanding of GPCR biology. GPCRs, including olfactory receptors, typically function through the activation of heterotrimeric G-proteins, which in turn modulate various downstream effectors such as adenylate cyclase, leading to changes in intracellular second messenger levels (e.g., cAMP). The modulation of these downstream pathways can influence the receptor's function, either enhancing or inhibiting its activity.
In the context of Olfr829, indirect modulators would be compounds that influence the signaling pathways associated with GPCRs but may not bind directly to Olfr829. These could include antagonists or agonists of other GPCRs, as GPCR-mediated pathways often intersect and regulate each other. For example, compounds that alter the levels of cAMP within the cell can indirectly influence the signaling cascades initiated by olfactory receptors. Furthermore, the modulation of other signaling molecules and pathways that interact with GPCR signaling, such as those involving calcium ions or protein kinases, could also impact the function of olfactory receptors. Given the vast diversity of GPCRs and their ligands, as well as the complex network of intracellular signaling pathways, the indirect modulation of Olfr829 can occur through various mechanisms. It is important to note that the compounds listed above are selected based on their known actions on different GPCRs and their potential to indirectly influence GPCR-mediated signaling pathways. The field of olfactory receptor research, including the study of Olfr829, is an area of ongoing investigation. Advancements in understanding the specific roles and signaling mechanisms of these receptors will aid in the identification of more targeted and specific modulators.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
A non-selective beta-adrenergic receptor antagonist, Propranolol binds to these GPCRs, leading to decreased adenylate cyclase activity. This can indirectly influence GPCR-mediated olfactory signaling pathways, potentially modulating receptors like Olfr829. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol is a non-selective beta-adrenergic antagonist with alpha-1 blocking activity. By inhibiting these GPCRs, it alters cAMP levels, which may indirectly affect the signaling of GPCRs such as Olfr829. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
A selective 5-HT3 receptor antagonist, Ondansetron blocks serotonin receptors, another class of GPCRs. This inhibition can modulate downstream signaling pathways that might intersect with those involving olfactory receptors like Olfr829. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
An angiotensin II receptor antagonist, Losartan blocks AT1 receptors, a subset of GPCRs, potentially affecting downstream signaling pathways that could indirectly influence olfactory receptor functioning. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
An alpha-2 adrenergic receptor antagonist, Yohimbine inhibits these GPCRs, potentially modulating adenylate cyclase activity and cAMP levels, which could indirectly affect olfactory receptors like Olfr829. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
A mixed alpha/beta adrenergic antagonist, Labetalol's action on these GPCRs could lead to changes in intracellular signaling pathways that may intersect with those of olfactory receptors. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
A selective beta-2 adrenergic agonist, Salmeterol's action on GPCRs could indirectly influence other GPCR-mediated pathways, including those of olfactory receptors. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
A histamine H2 receptor antagonist, Cimetidine inhibits these GPCRs, potentially influencing cAMP levels and downstream signaling that might affect olfactory receptor function. | ||||||
(S)-Timolol Maleate | 26921-17-5 | sc-203297 sc-203297A | 100 mg 250 mg | $61.00 $126.00 | ||
A non-selective beta-adrenergic receptor antagonist, Timolol's inhibition of these GPCRs could indirectly modulate signaling pathways related to olfactory receptors. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $40.00 $92.00 $122.00 | 4 | |
An angiotensin II receptor blocker, Valsartan's action on AT1 GPCRs could affect downstream signaling pathways, potentially impacting olfactory receptor functioning. | ||||||